Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 927 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Interventions
CAM-H2
Drug
Lead sponsor
Precirix
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Duarte, California • Stanford, California • Washington D.C., District of Columbia + 6 more
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
Interventions
Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection
Drug · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate, Laboratory Biomarker Analysis, Neoadjuvant Therapy, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Chicago, Illinois • Iowa City, Iowa + 5 more
Conditions
Breast Cancer
Interventions
Cabozantinib, Fulvestrant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Conditions
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Monterey, California • Orange, California + 19 more
Conditions
Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer, Stomach Cancer
Interventions
Zanidatamab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Orange, California • Houston, Texas
Conditions
Breast Cancer
Interventions
paclitaxel, Trastuzumab, Pertuzumab, carboplatin, Breast surgery, AC
Drug · Procedure
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Providence, Rhode Island
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
pembrolizumab, trastuzumab, capecitabine, cisplatin, Oxaliplatin, 5-Fluorouracil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Conditions
Breast Cancer, HER2 Positive Breast Cancer
Interventions
MM-302, Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
70
States / cities
Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 58 more
Conditions
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions
Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
32
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
Conditions
Solid Tumors That Overexpress HER2 (HER2 Positive)
Interventions
FS102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Memphis, Tennessee + 2 more
Conditions
Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
DC1 Vaccine, WOKVAC Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
40
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Ian E. Krop, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Hooksett, New Hampshire
Conditions
Breast Cancer
Interventions
Left Ventricular Ejection Fraction
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Conditions
Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions
BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 13 more
Conditions
Breast Cancer
Interventions
Everolimus
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Metastatic Breast Cancer
Interventions
GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts
Conditions
Breast Cancer
Interventions
U-13C-glucose
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, breast biopsy, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Conditions
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
everolimus, Placebo, vinorelbine, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more
Conditions
Breast Cancer
Interventions
KIBUR MICRODEVICE, anthracycline and taxane based chemotherapy
Device · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more